Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

ZEAKAL DELIVERS SYNERGISTIC INNOVATION TO ENHANCE SUSTAINABILITY OF CORN PRODUCTION

ZeaKal

ZeaKal today announced the successful development of its groundbreaking PhotoSeed™ technology in corn, improving the crop’s oil and sustainability profile without compromising yield or protein. With the immediate implementation of PhotoSeed corn’s route to market, ZeaKal aims to redefine the value proposition of this vital crop for growers, industry, and consumers alike. In first year replicated field trials, PhotoSeed increased corn oil composition by an average of 23 percent. PhotoSeed enhances a plant’s photosynthetic capacity, capturing more CO2 and sunlight. This additional carbon capture increases oil production without taking away the energy necessary to maintain modern yields. Despite tremendous demand, previous efforts to boost oil content without compromising yield have eluded agribusinesses. ZeaKal now introduces the first viable solution. Han Chen, co-founder and CEO of ZeaKal, emphasized the imperative for accelerated innovation to meet the escalating demand for sustainable corn oil production. "This trait technology allows us to elevate the overall value of U.S. corn and creates a differentiated, value-added product that addresses industry demand," said Chen. “U.S. farmers need innovation faster if we hope to compete in a challenging global commodity market. While we cannot change sunlight availability and geography for our growers, we can bring a latitude advantage to them through genetics.” Corn, occupying 90 million acres in the United States and ranking among the most crucial crops globally, serves as a cornerstone for food, feed, and fuel feedstocks. The FAO forecasts a 70% surge in global demand for sustainable food and feed, and other projections indicate that renewables will constitute 43% of total energy within a decade. Together, this underscores the urgency for plant-based energy, which offers inherent benefits for aviation fuel and renewable diesel that other innovations cannot offer. Expanded Gro Alliance Partnership Accelerates Farmers’ Access to PhotoSeed Corn Hybrids In 2022, ZeaKal set a path to restore value across the soy supply chain by creating a closed loop U.S. system to capture and share premiums from better composition, processing advantages, and improved sustainability metrics with farmers and producers – called the NewType model. PhotoSeed corn follows the model’s success starting with integration into Gro Alliance’s extensive germplasm collection, breeding program, and fully integrated seed production. “For too long, extended periods of depressed commodity prices coupled with rising input costs have magnified risk for U.S. farmers. With ZeaKal 's breakthrough technology and our expanded capacity and partnerships, we are setting our sight on the better seed for the entire value chain; farmers, seed companies and end-users,” said Jim Schweigert, president of Gro Alliance, which recently expanded its germplasm pool and secured a partnership with an advanced sorting technology company. Just as in soybeans, nutrient, and energy densification in PhotoSeed corn translates to more carbon captured in the seed. With higher oil production that does not require additional inputs or land, PhotoSeed becomes a sustainability embedded trait that has the potential to lower the carbon intensity score of the crop. “The future of agriculture must be grounded in innovation that democratizes value creation or else agriculture will not be responsive to demands for improved sustainability, nutrition, and energy,” said Chen. “Starting with the grower, our vision is to leverage trait technology and replicate our NewType model to ensure value creation and sharing across the entire supply chain.” PhotoSeed corn commercialization is expected in the 2027 growing season. For more information about ZeaKal and PhotoSeed technology, or to become part of the NewType model, visit zeakal.com. ABOUT ZEAKAL: At ZeaKal, we are building a value driven “NewType” of agriculture to harmonize the needs of farmers, consumers, and our planet. Our flagship plant trait technology, PhotoSeed™, helps crops capture more carbon and sunlight, leading to healthier, nutrient-rich food and feed grown on a smaller environmental footprint. We go beyond science to make affordable nutrition more sustainable, with marketable differentiation for growers. Discover how we are transforming carbon to nutrition: zeakal.com or @zeakal on Twitter. Contact Details AgTech PR for ZeaKal Jennifer Goldston jennifer@agtechpr.com Company Website https://www.zeakal.com

March 19, 2024 08:30 AM Central Daylight Time

Image

DREW BREES AND COPPER COMPRESSION TOUCHDOWN AT WALGREENS, REVOLUTIONIZING RECOVERY FROM ONLINE INTO AISLE

Copper Compression, LLC

In an exciting play for the recovery game, Copper Compression, the leading online health and wellness compression wear brand endorsed by football legend Drew Brees, announces today its expansion into over 1500 select Walgreens stores nationwide. This strategic partnership not only enhances Copper Compression’s accessibility, but also delivers new winning solutions for Walgreens’ health conscious consumers seeking premium wellness products not typically found at retail locations. “Partnering with one of the largest chain drug stores marks a significant milestone for Copper Compression and underscores the evolution of our brand,” says Super Bowl Champion, Drew Brees. “I’ve personally experienced faster recovery while using Copper Compression. Having these products available at Walgreens will be life-changing for people dealing with pain and in need of effective all-natural relief.” Walgreens will now carry a selection of six Copper Compression products featuring Brees including, the Recovery Shoulder Brace (an Amazon Best Seller), Calf Sleeves, a universal Finger Splint which features medical grade aluminum and the introduction of Coppervibe™, the latest innovation in wearable tech that combines Vibration and Heat for hands, back and knee relief. Copper Compression continues to garner recognition by millions of online fans for its lab-tested nylon compression all which is infused with the maximum copper advantage. Its full collection of products are also FDA approved and certified antimicrobial by the EPA; these standards lead to explosive growth, rave reviews and a loyal customer base which include celebrities Anna Wintour, DJ Khaled, Kid Rock and Kaley Cuoco. “The trend from online to inline continues to reflect a dynamic transformation in the retail landscape," adds Vincent Porpiglia, President of Hero Brands, “Fan favorite digital brands continue to emerge and prove themselves alongside legacy brands at brick-and-mortar. Copper Compression stands at the forefront of this movement, delivering its premium recovery solutions to your neighborhood Walgreens” About Copper Compression New York City-based Copper Compression is a health and wellness brand that designs, manufactures, and distributes the most diverse portfolio of cutting-edge copper-infused compression wearables tailored for pain relief and performance recovery. The company’s 100 unisex products include groundbreaking solutions for arthritis, tendonitis, and plantar fasciitis. Established in 2015, Copper Compression has served over 10 million satisfied customers and has been featured in Forbes, ESPN, Women’s World, US Weekly, and Sports Illustrated for its renowned commitment to effective, all-natural pain relief. Having amassed over 300,000+ authentic customer reviews from their online-first business model, Copper Compression swiftly expanded its success to over 10,000 national retail locations in less than 3 years, partnering with industry giants like Walmart, Walgreens, Publix, Ingles, and Harris Teeter. Copper Compression earned seven best seller badges on Amazon.com for its top-rated Half-Finger Arthritis Gloves and Arch Supports. Follow @CopperCompression on Instagram, TikTok and Facebook. Note to Editors: Photos available Here. Press Contacts: Nathan Lindsey NLindsey@adjmi.com 203.376.8154 Sarah Leheny SLeheny@adjmi.com 631.834.2815 Contact Details Copper Compression Joey Braha JBraha@adjmi.com Copper Compression Nathan Lindsey +1 203-376-8154 nlindsey@adjmi.com Copper Compression Sarah Leheny +1 631-834-2815 Company Website https://www.coppercompression.com/

March 19, 2024 08:30 AM Eastern Daylight Time

Video Image

NCMA's Announces New Members to their National Committee

National Contract Management Association

At the National Contract Management Association (NCMA), the focus on providing high-quality resources— events, professional certifications, local networking, and the ANSI-approved Contract Management Standard™ —that positively advance and expand the contract management profession remains the top priority. To help to continue strengthen the association’s strategic direction and growth, NCMA is excited to announce its new National Committee Members, who bring a wealth of experience and expertise to guide their endeavors forward. “Our National Committee Members are essential in providing a platform for meaningful planning and growth for our members and association,” said NCMA’s Board-Chair Elect, Heather Gerczak. “They will be instrumental in inspiring innovation and refining our strategy. I am thrilled to welcome our new members and am excited to collaborate in Program Year 2025.” The National Committee members are seasoned professionals with impressive track records in their respective fields. NCMA welcomes: Joann Campbell-Maher, CPCM, CFCM, CCCM, Director of Contracts, SRC Inc., Chapter: Leatherstocking Chapter Will Cannon, Director of Business Operations, General Atomics Chapter: San Diego Jim Doss, Fellow, CPCM, CFCM, Director of Contracts, BlueHalo, Chapter: Tysons Derek Ebona, CPCM, Chief of the Contracting Office, Program and System Support for Contracting and Procurement Office, Defense Counterintelligence and Security Agency, Chapter: Tysons Jessica Johnson, CPCM, CFCM, VP, Services Contracts at Red River Technology, Chapter: Dulles Corridor Wanda Wallace, CPCM, CFCM, Senior Contracts Manager at Magellan Federal, Chapter: Jacksonville This year’s National Committees Members were elected through a competitive application and voting process. These members make a lasting impact on NCMA. The Committees are made up of five groups including audit and risk, governance and ethics, member engagement, professional development and certification, and strategic planning. All who have served have played an instrumental role in helping to shape the associations’ strategy and direction. The National Contract Management Association (NCMA) – www.ncmahq.org – has grown as a professional society whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. Contact Details Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

March 19, 2024 05:00 AM Eastern Daylight Time

Image

AGBOOST SCALES AI-ENABLED GENETIC DATA ANALYSIS SOFTWARE FOR CATTLE PRODUCERS

AgBoost

After years of product development and field testing, AgBoost announced the global commercial expansion of its cloud-based data analysis platform that helps cattle producers interpret genomic data for selective breeding, health, market value and nutrition management. Despite a 65% increase in U.S. beef herd productivity over five decades, according to United Stated Department of Agriculture (USDA), rising demand for sustainably produced meat and shrinking profit margins underscore the importance of genetic data for herd efficiency. "Too often, cattle producers invest in DNA technology without unlocking its full potential," said Sean Akadiri, founder and CEO of AgBoost, at the 2024 Animal AgTech Innovation Summit and World Agri-Tech Innovation Summit. "Our platform revolutionizes decision-making, empowering ranchers with faster, more precise choices. By putting genetics at their fingertips, we're reducing the average $2,000 loss per calf during breeding and development, giving ranchers a decisive advantage over the competition.” Traditionally, breeding decisions rely on visual appraisals and multi-generation written records of estimated genetic merit. AgBoost's software combines genomic and production data, including live birth weight and diverse phenotypic information, for individual animals. Users can track animals individually or group them, such as in replacement heifer groups. By selecting specific traits, producers gain a comprehensive view to inform feeding, animal health, and marketing decisions effectively. “Genomic testing data can feel like deciphering hieroglyphics to most producers. But AgBoost transforms complexity into simplicity, presenting data in a visual wheel that sparks meaningful conversations. Now, we can swiftly identify the top bulls with complementary traits for desired calves,” said Nick Jorgensen, CEO and CFO of Jorgensen Land and Cattle, who not only licenses the platform for its large seed stock operation but also invested in the company. Seedstock cattle producers depend on analytics for marketing in bull and production sales. AgBoost visually showcases genetic value and identifies DNA-linked traits, like production, maternal, and carcass traits, aiding in sorting and selecting specific characteristics. The tool also allows for scenario planning, including establishing keep/cull lines to distinguish the top and bottom of the gene pool. Poised for Rapid Expansion into New Geographies and Livestock Introduced to U.S. cattle producers in 2018, AgBoost now holds millions of genomic data records for individual cows. With recent patent approvals, the company aims to expand into top-producing markets like Brazil, Canada, China, and the United Kingdom. The global beef market, valued at $526.50 billion in 2023, is projected to grow at a 4.2 percent CAGR by 2030. Currently, AgBoost supports all sizes of seedstock and commercial cow/calf producers, regardless of breed association, with an interactive pedigree and sire link, with a breeding suggestion calculator coming in late 2024. As pioneers in the market, the company intends to broaden individual producer subscriptions, enterprise licensing agreements, and tailor the platform for additional livestock and related industries to meet current demand. For more information, visit www.Ag-Boost.com. About AgBoost Established in 2013 by engineers and cattle producers as a subsidiary of the animal agtech leader, Agric-Bioformatics, Inc., AgBoost pioneers affordable, user-friendly genetic management tools for livestock producers worldwide. Our comprehensive software streamlines the entire process—from ordering tests to interpreting data for actionable insights and creating effective marketing tools. At AgBoost, our mission is clear: to prioritize producers by empowering them to own and comprehend their data, unlocking maximum growth potential for the future. To learn more or request a demo, visit www.Ag-Boost.com. Contact Details AgTech PR for AgBoost Jennifer Goldston jennifer@agtechpr.com

March 18, 2024 12:17 PM Central Daylight Time

Image

Abingdon Health CEO discusses strong interim results, robust pipeline and growth strategy

Abingdon Health PLC

Abingdon Health PLC (AIM:ABDX) CEO and co-founder Chris Yates discusses the company's interim results and business operations in an interview with Proactive's Stephen Gunnion. Abingdon Health is a lateral flow, contract development, and manufacturing organisation (CDMO), supporting customers from product ideation to commercial success. It offers services including development, scale-up manufacturing, regulatory and analytical laboratory provision, and packaging. Yates said a 117% revenue increase to £2.4 million during the interim period was primarily driven by its CDMO division. This growth was attributed to increases in development, operational revenues, and the emergence of regulatory area revenues. Despite an inflationary environment, Abingdon Health managed to maintain stable operating costs, resulting in improved gross margins to over 50%. The company has a robust opportunity pipeline with 29 ongoing projects, emphasizing its fully integrated solution's appeal to customers. Yates also highlighted a good start to the second half of the year, with revenues expected to grow significantly while controlling costs to enhance operating profit performance. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

March 18, 2024 07:10 AM Eastern Daylight Time

Video

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Benzinga

By Faith Ashmore, Benzinga Pancreatic cancer has, unfortunately, been in the news lately due to the rising rates of early-onset cancer, especially in young people. The gastrointestinal cancer, which has a 12% five-year survival rate, is expected to become the second-highest cause of cancer-associated deaths in 2030 in the U.S. In 2024, it is projected that 64,440 Americans will be diagnosed with pancreatic cancer. The global market size for pancreatic cancer was valued at $2.22 billion in 2022, and it is expected to be worth around $7.91 billion by 2032. Despite the multi-billion dollar market size, the industry is expected to grow at 13.6% through 2032, and pancreatic cancer still needs more therapeutic options – especially for advanced cases or when existing treatments don’t yield the desired results. Theriva Biologics (AMEX: TOVX) is a biotech company that is looking to use adenoviruses to help treat pancreatic cancer. Adenoviruses are a class of viruses with an established safety profile. They are highly prevalent in the environment, making them ideal candidates for therapeutic use in the cancer field. Theriva Biologics' lead product candidate, VCN-01, is a uniquely modified human adenovirus designed for systemic delivery to treat different types of cancer. Theriva Biologics reports that phase 1 clinical trials of VCN-01 have shown promising results for the treatment of several additional indications apart from pancreatic cancer, such as retinoblastoma, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) in combination with chemotherapy and immunotherapies. Currently, the company is conducting a phase 2b clinical trial of VCN-01 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. It is on track to complete enrollment into the VIRAGE Study by the first half of 2024. In the first quarter of 2024, a Drug Monitoring Committee (DMC) conducted a thorough safety review of VCN-01, and found that the VCN-01 safety profile permitted the VIRAGE study to continue without modification. By the second half of 2024, Theriva Biologics aims to perform an interim analysis of the data obtained from the VIRAGE Study. Pancreatic cancer presents several unique challenges that contribute to its high mortality rate and the difficulty in managing the disease. One major challenge is the aggressive nature of pancreatic cancer, which often spreads to other organs before being diagnosed. Approximately 50% of patients are diagnosed when the cancer has already metastasized, resulting in advanced-stage disease. Pancreatic cancer is also known for causing nonspecific symptoms, making it challenging to detect in its early stages. VCN-01 has a systemic delivery approach, which means it can target both the main tumor and distant metastases, which makes it a promising therapeutic option for advanced and difficult-to-treat cancers like pancreatic cancer. If the company can successfully harness the benefits of adenoviruses, it will present suffering patients around the globe with a novel solution to extend their lives. Featured photo by Olga Kononenko on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 14, 2024 08:20 AM Eastern Daylight Time

Image

UNOS welcomes new seven-member board of directors

United Network for Organ Sharing

On Friday, March 8, 2024, the United Network for Organ Sharing (UNOS) announced the seven members of its new board of directors, who begin their terms on March 30, 2024. For the first time in nearly 40 years, UNOS’ board of directors will be independent from the Organ Procurement and Transplantation Network’s (OPTN) board of directors. The new UNOS board takes effect the day after UNOS’ current OPTN contract with the federal government ends. The creation of a new, independent UNOS board eliminates any conflict of interest in the governance of the OPTN. Currently, the same 42 people oversee both UNOS and the OPTN. The board separation represents a significant change in governance structure, and it has received wide-ranging support – from HRSA, from members, and even from critics of the current OPTN system - as it benefits the entire transplant community. Board separation also is in line with HRSA’s own Modernization Initiative. While HRSA is working to finalize plans for the OPTN board when the current contract expires, UNOS has followed through on its commitment to remove the conflict of interest that has been in place for decades by announcing its new board of directors. Now, after working on board separation plans with HRSA for years, UNOS remains confident that HRSA will act by March 30 to finalize this critical change that is best for the entire transplant community. “Having independent and distinct boards will appropriately allow each organization to benefit from board members who have a singular focus on the mission of the organization they support without conflicts of interest that may cause unnecessary challenges,” said Maureen McBride, Ph.D., CEO of UNOS. “I look forward to working with our new UNOS board, as well as the OPTN board, to not only continue our lifesaving work within the U.S. donation and transplant system, but to also expand our reach as a company to help improve the health and lives of more people around the globe.” UNOS’ new board members were selected for their diverse range of expertise and experience in business strategy, health care, information technology and information security, and the organ donation and transplant system. The members are: Sue Dunn, former CEO of Donor Alliance Bapu Jena, M.D., Ph.D., professor of health care policy at Harvard Medical School, internist at Massachusetts General Hospital Maryl Johnson, M.D., professor at the University of Wisconsin School of Medicine Irene Kim, M.D., director of the Comprehensive Transplant Center at Cedars-Sinai Jake Kouns, founder of RVAsec James Pittman, assistant vice president of transplant and dialysis services for HCA Healthcare Marie Quintero-Johnson, retired vice president of corporate development for Coca-Cola and kidney recipient Establishing a UNOS board that is distinct from the OPTN board is aligned with HRSA’s Modernization Initiative, calls from Congress to separate the boards, and UNOS’ Action Agenda. UNOS worked with HRSA as UNOS took action to establish its new governance structure separate from the OPTN: June 22, 2021 – UNOS met with HRSA to present on the establishment of a separate OPTN board. January 10, 2023 – UNOS sent a letter to HRSA Administrator Carole Johnson expressing a shared desire to create two distinct boards of directors. The letter noted that UNOS sent the contracting officer a request for a “modification to the current OPTN contract. The proposed modification would assign UNOS a task to develop a plan to separate the OPTN Board of Directors from UNOS’ Board of Directors.” UNOS asked the administrator to approve the contract modification noting that “the end of the current contract, September 29, 2023, would be an ideal time to complete the separation of the boards.” March 22, 2023 – HRSA announced its OPTN Modernization Initiative, which noted that as part of the effort, HRSA will work to ensure the OPTN board of directors “has greater independence.” May 2023 – HRSA issued a contract modification directing UNOS to submit an OPTN Board Independence Plan that complies with the National Organ Transplant Act and the OPTN Final Rule and included required activities, with timelines and milestones, to incorporate the OPTN as an independent legal entity governed by the OPTN board of directors. July 14, 2023 – UNOS submitted its OPTN Board Independence Plan. July 20, 2023 – The Senate held a hearing focused on the Securing the U.S. Organ Procurement and Transplantation Network Act, which according to the bill’s sponsor will for the first-time mandate an independent Board of Directors to oversee OPTN separate from the contract holder. July 27, 2023 – HRSA issued a statement on the OPTN reform law: "The Health Resources and Services Administration shares Congress’ goal of making the Organ Procurement and Transplantation Network (OPTN) work better for the more than 100,000 people on the waiting list for organs. Individuals on the wait list, organ donors, and their families deserve an OPTN governed by an independent, representative board…” September 28, 2023 – HRSA executed a unilateral extension of UNOS’ contract through March 29, 2024. October 30, 2023 – UNOS and HRSA met at UNOS’ request regarding board separation effective March 30, 2024, the day after UNOS’ contract ends. HRSA indicated it cannot dictate the corporate governance structure of a private entity. November 29, 2023 – UNOS and HRSA had a follow-up meeting at UNOS’ request regarding board separation. December 5, 2023 – UNOS board voted to establish a new governance structure distinct from the OPTN Board, a decision made in the best interest of patients and the nation’s organ donation and transplant system. The board made the effective date of this action March 30, 2024, to align with the end of UNOS’ 6-month contract extension. December 13, 2023 – UNOS and HRSA had a follow-up meeting at UNOS’ request regarding board separation. December 2023 – HRSA reiterated its commitment to an independent OPTN board: “For nearly 40 years, the Board of Directors for the Organ Procurement and Transplantation Network (OPTN) has been comprised of the same individuals who serve as the Board of Directors for the private entity that has held the OPTN contract. No formal requirements existed to protect against conflicts of interest resulting from this shared role.” February 22, 2024 – UNOS membership ratified the UNOS board decision to establish a new UNOS governance structure. March 29, 2024 – UNOS’ current contract with HRSA ends. Although the federal government’s timeline for implementing its OPTN Modernization Initiative has shifted, UNOS, under new leadership, has remained committed to being a good partner to the administration, Congress and stakeholders to change the current governance structure that requires UNOS board members to serve as OPTN board members. Effective March 30, 2024, OPTN board members will not have a fiduciary duty to UNOS as a non-profit organization. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 12, 2024 02:46 PM Eastern Daylight Time

atai Life Sciences advances VLS-01 for treatment-resistant depression

atai Life Sciences

atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion. Rao explained that VLS-01 is a formulation of DMT, the active component in ayahuasca, known for its short-duration psychedelic effects. The innovation lies in its delivery method, an oral transmucosal film, resembling a Listerine strip, which dissolves inside the mouth over 20 minutes, providing a patient-friendly alternative to intravenous administration. Rao said this approach is designed to enhance the patient and healthcare provider experience, especially in settings not equipped for IV treatments. The ongoing Phase 1B trial seeks to confirm VLS-01's safety, tolerability, pharmacokinetics (PK), and pharmacodynamics, aiming for a psychoactive effect lasting 30-45 minutes with patients returning to baseline within two hours post-administration. Rao said this trial format follows the US treatment paradigm established by Spravato (esketamine) for depression. The trial will involve 16 healthy volunteers to assess the drug's impact, setting a baseline with intravenous DMT before testing up to three oral doses of VLSI-01. Initial results are expected in the second half of the year, with plans to proceed to Phase 2 trials involving patients with treatment-resistant depression to evaluate the compound's efficacy further. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 12, 2024 12:35 PM Eastern Daylight Time

Video

Blind Review and PathPresenter Partner to Eliminate Expert Witness Bias in Pathology Malpractice Cases

PathPresenter

Blind Review, LLC, the secure digital platform for eliminating expert witness bias, and PathPresenter, the global image sharing platform for pathology, today announced a strategic partnership ushering digital pathology into the medical malpractice space. This alliance will revolutionize how pathology expert reviews are conducted in malpractice cases, transforming it from the old-school, glass-slide model to a cutting-edge, digital model that increases efficiency, streamlines access, and simplifies the traditional pathology review. Blind Review specializes in removing hindsight, financial, and party-identity bias from expert witnesses through a proprietary digital platform and customized process. Once onboarded to the platform, experts are digitally placed into the shoes of the treating physician. As the care-story unfolds, the expert’s opinion is captured at each critical point of care, all while shielding the identity of the attorney, client, and care outcome. Importantly, the process prevents the expert from knowing what comes next without first committing to an opinion based only on the records available at that point in the care – eliminating hindsight bias. PathPresenter is a secure and scalable multi-tenant enterprise pathology workflow platform that has been developed by pathologists with deep domain knowledge and experience. Trusted by over 45 tier-one medical institutions, PathPresenter is the most comprehensive image management/viewing suite available for clinical care, remote consultations, education, and research. Pathologists play a critical role in reviewing medical malpractice cases for disease diagnosis or when timing of an injury or cause of death is in question. PathPresenter has taken the desktop microscope and transformed it into a state-of-the-art digital viewer that pathologists can access anytime, anywhere to review microscopic evidence in a legal case. Utilizing PathPresenter’s cloud-based, clinical consultation platform, Blind Review’s proprietary process is far more efficient and eliminates the risks and limitations that come with glass slides. “Juror’s trust in experts has fallen to levels below where they were before the pandemic, and we continue to see very large, unexpected verdicts,” says Blind Review’s CEO and attorney-founder, Stephanie Franckewitz. “Independent research supports that a blinded expert doubles the chances of a favorable verdict because jurors perceive them as significantly more credible. We are proud to partner with PathPresenter, and we are in good company, as many of the world’s elite medical institutions use PathPresenter on a day-to-day basis in their pathology departments.” “PathPresenter’s partnership with Blind Review brings the practice of expert pathology review within the medical malpractice space into the 21st century,” adds Patrick Myles CEO of PathPresenter. “Whether in the courtroom or in the pathology lab, expert opinion is all about trust. By partnering with Blind Review, we’re enabling a never-before-seen way to restore jurors’ trust in experts.” About Blind Review, LLC Blind Review is the digital platform that provides the infrastructure to eliminate expert witness bias in medical malpractice cases. We deliver a strong competitive advantage to the trial teams who share our vision: Unbiased, reliable, and trustworthy expert opinions. Blind Review digitally places the expert into the shoes of the treating healthcare provider. As the care-story unfolds, the expert’s opinion is captured at each critical point of care, all while shielding the identity of the attorney, client, and care outcome. Simple and intuitive, our cloud-based interface allows robust customization, with the ability to deliver our unique Blind Review process across multiple specialties within a single case. Blind Review’s platform includes seamless integration with a secure cloud-based Radiology PACS system and Digital Pathology system, with state-of-the-art viewers. About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 45+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. ### Media Inquiries: Michelle Rupp 501-658-9277 or michelle@memorableresultsmedia.com PathPresenter is the global image sharing platform for pathology. We are on a mission to democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 45+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. For more information visit www.pathpresenter.com. Contact Details Cory Batenchuk +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.com

March 11, 2024 01:00 PM Eastern Daylight Time

1 ... 11 12 13 14 15 ... 142